Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial
Six months of low-dose colchicine prophylaxis when starting allopurinol using the "start-low go-slow" approach is unlikely to be cost-effective over 12 months.
Authors
- J. Haxby Abbott (ORCID: https://orcid.org/0000-0001-6468-7284)
- Ross Wilson (ORCID: https://orcid.org/0000-0001-8505-8081)
- Lisa K. Stamp (ORCID: https://orcid.org/0000-0003-0138-2912)
- Yana Pryymachenko (ORCID: https://orcid.org/0000-0002-0259-1217)
- Nicola Dalbeth (ORCID: https://orcid.org/0000-0003-4632-4476)
Institutions
- University of Auckland (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1002/acr.25631
- Citations
- 1
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- University of Otago
- Health Research Council of New Zealand